Diagnostic value and immune microenvironment regulatory network of metabolic reprogramming in chronic rhinosinusitis with nasal polyps identified by multidimensional transcriptome integration and machine learning - Scorecard - MDSpire

Diagnostic value and immune microenvironment regulatory network of metabolic reprogramming in chronic rhinosinusitis with nasal polyps identified by multidimensional transcriptome integration and machine learning

  • By

  • Li Zhao

  • Xiang Jiang Meng

  • Xu Liang

  • Guang Mei Yuan

  • Li Shi

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating the Diagnostic Potential and Immune Microenvironmental Interactions of Metabolic Reprogramming in Chronic Rhinosinusitis with Nasal Polyps through Multidimensional Transcriptomic Analysis and Machine Learning Techniques

At a Glance

CategoryDetail
ConditionChronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Key MechanismsMetabolic reprogramming and immune microenvironment interactions
Target PopulationPatients with CRSwNP, often with comorbid asthma
Care SettingClinical and research settings focusing on chronic inflammatory diseases

Key Highlights

  • Identified 21 differentially expressed genes (DEGs) related to metabolic reprogramming in CRSwNP.
  • Eight hub genes (ERBB4, FBP1, HMGCS2, LYZ, NDRG2, PIP, PYCR1, SLC43A1) were identified with high diagnostic performance (AUC = 0.979).
  • Single-cell RNA sequencing revealed distinct expression patterns of hub genes across immune cell subsets.
  • Lower expression of FBP1, LYZ, and NDRG2 identified as potential risk factors for CRSwNP.
  • Study provides insights into metabolic mechanisms driving CRSwNP pathogenesis.

Guideline-Based Recommendations

Diagnosis

  • Current diagnostics rely on imaging, endoscopic evaluation, and symptom scoring.

Management

  • Standard treatments include corticosteroids and surgical approaches, though they have high recurrence rates.

Monitoring & Follow-up

  • No specific molecular tools currently exist for early diagnosis or subtyping of CRSwNP.

Risks

  • High rates of recurrence and poor long-term outcomes associated with standard treatments.

Patient & Prescribing Data

Patients diagnosed with CRSwNP, often with asthma and allergic rhinitis.

Biologic therapies are available but limited by cost and varied responses.

Clinical Best Practices

  • Utilize machine learning and bioinformatics for identifying potential biomarkers in CRSwNP.
  • Consider metabolic reprogramming as a therapeutic target in CRSwNP management.

Related Resources & Content

Original Source(s)

Related Content